PRONEUROGEN IN THE NEWS
PRONEUROGEN FOUNDER, DR. MEREDITH HAY, AND COLLEAGUES PUBLISH NEW REPORT IN THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS SHOWING PNA5 AS A NOVEL TREATMENT FOR VASCULAR COGNITIVE IMPAIRMENT.(http://jpet.aspetjournals.org/content/369/1/9).
PRONEUROGEN FOUNDER, DR. MEREDIT HAY, AND COLLEAGUES AWARDED NEW USPTO PATENT 10,72,908. THE INVENTION PROVIDES A METHOD FOR USING A COMPOSITION COMPRISING AN ANGTIOTENSIN-(1-7) RECEPTOR AGONIST TO TREAT COGNITIVE DSYFUNCTION OR IMPAIRMENT DUE TO INCREASES IN INFLAMMATION, CYTOKINE PRODUCTION AND BRAIN INFLAMMATION.
UNIVERSITY OF ARIZONA PHARMACOLOGY HEAD DR. TODD VANDERAH AND PRONEUROGEN FOUNDER DR. MEREDITH HAY AWARDED $730 THOUSAND, 3-YEAR GRANT FROM ARIZONA DEPARTMENT OF HEALTH TO ADVANCE PRONEUROGEN PEPTIDES PNA5 AND PNA6 TO TREAT NEUROPATHIC AND CANCER PAIN.
THE JAPAN PATENT OFFICE AWARDS NEW PATENT TO DRS. HAY, KONHILAS AND BARNES FOR THE USE OF ANG-(1-7) TO TREAT COGNITIVE IMPAIRMENT CAUSED BY INFLAMMATORY DISEASE, JAPAN 6254692. THE PATENT IS LICENSED EXCLUSIVELY TO PRONEUROGEN.
THE U.S. PATENT AND TRADEMARK OFFICE HAS AWARDED TWO PATENTS TO THE UA BASED ON THE TEAM’S NOVEL APPROACH TO TREATING DISEASES CAUSING MEMORY LOSS AND COGNITIVE IMPAIRMENT. U.S. PATENT 9,670,251 WAS AWARDED JUNE 6 AND U.S. PATENT 9,796,759 WAS AWARDED OCT. 24. THE PATENTS, BOTH LICENSED TO PRONEUROGEN, SERVE AS THE CORNERSTONE FOR PRONEUROGEN’S DRUG DEVELOPMENT PROGRAM.
PRONEUROGEN FOUNDER, DR MEREDITH HAY, AND UNIVERSITY OF ARIZONA RESEARCHERS BEGIN ENROLLMENT IN PHASE 2 TRIAL FOR PATIENTS AT RISK FOR COGNITIVE IMPAIRMENT FOLLOWING CARDIAC BYPASS SURGERY. https://uanews.arizona.edu/story/ua-team-tackles-better-brain-health
UNIVERSITY OF ARIZONA AWARDED $2.8 MILLION, 4-YEAR GRANT FROM NIH FOR PHASE 2a CLINICAL TRAIL FOR COGNITION. ProNeurogen president, Dr Meredith Hay, University of Arizona Sarver Heart Center Director, Dr Nancy Sweitzer, and University of Arizona Head of Department of Psychology, Dr Lee Ryan, awarded a $2.8 million NHLBI grant to studyefficacy of PNA1 to treat cognitive impairment in cardiac bypass patients.
PRONEROGEN PRESIDENT, DR MEREDITH HAY AND UA TEAM PUBLISHES MEMORY ENHANCING EFFECTS OF ANG-(1-7) IN PRECLINICAL MODEL OF VASCULAR DEMENTIA https://www.ncbi.nlm.nih.gov/pubmed/28054808 Patients with congestive heart failure (CHF) have increased hospital readmission rates and mortality if they are concomitantly diagnosed with cognitive decline and memory loss. Results of the work demonstrate that CHF-induced cognitive impairment is attenuated by treatment with systemic Ang-(1-7).
PRONEUROGEN ADVISORY BOARD MEMBER, DR TODD VANDERAH PUBLISHES PAPER ON THE NOVEL EFFECTS OF ANG-(1-7) TO INHIBIT BONE-CANCER PAIN. http://journals.lww.com/pain/Fulltext/2016/12000/Angiotensin__1_7__Mas_receptor_as_an.11.aspx. Cancer-induced bone pain is often severe because of enhanced inflammation, rapid bone degradation, and rapid disease progression. Data from this study suggest that Ang-(1-7)/MasR activation significantly attenuates CIBP, while lacking many side effects seen with opioids. Thus, Ang-(1-7) may be an alternative therapeutic strategy for the nearly 90% of patients with advanced-stage cancer who experience excruciating pain.
PRONEUROGEN AND UA SCIENTISTS BEGIN PHASE IIA ENROLLMNET FOR TREATMENT OF HEART FAILURE INDUCED COGNITIVE IMPAIRMENT
PRONEUROGEN NAMES GILLIAN THACKRAY AND ELIZABETH HOCKING TO BOARD OF DIRECTORS
PRONEUROGEN AND UA SCIENTISTS COMPLETE PRECLINICAL TESTING OF SECOND GENERATION NOVEL NEUROPEPTIDE. In an article published in Spectroscopy Conference, 2016, ProNeurogen’s second generation peptides show significantly improved serum half-lives and improved blood-brain-barrier penetration. The second generation peptides show improved efficacy in reversing inflammation/heart failure induced cognitive impairment in animal models of heart failure. In addition, these peptides are shown to reduce reactive oxygen formation and improves inflammatory profile in heart failure model.
PRONEUROGEN NEUROPROTECTIVE PEPTIDE IND APPLICATION FOR PNA1 GETS GO-AHEAD FROM FDA FOR PHASE II STUDY IN CARDIAC BYPASS PATIENTS.
PRONEUROGEN SIGNS EXCLUSIVE LICENSE WITH THE UNIVERSITY OF ARIZONA FOR PROPRIETARY TECHNOLOGY RELATING TO THE USE OF ANG (1-7) AND NOVEL DERIVATIVES DOR TREATMENT OF INFLAMMATION RELATED BRAIN DISORDERS.
PRONEUROGEN AND UA SCIENTISTS AWARDED ARIZONA ALZHEIMER’S CONSORTIUM AWARD
PRONEUROGEN OBTAINS PRECLINICAL DATA ON NOVEL NEUROPROTECTIVE PEPTIDES
Patients with congestive heart failure (CHF) have a much higher probability of mortality if they are concomitantly diagnosed with cognitive decline and memory loss. Furthermore, these patients have hospital readmission rates ranging from 40 to 50% within 6 months that are due, in part, to patient non- compliance with therapy as a result of cognitive impairment. Dr. Hay and colleagues have developed a small peptide that reversed cognitive impairment in an animal model of congestive heart failure.
NATIONAL HEART LUNG AND BLOOD- SMARTT PROGRAM AWARD TO PRONEUROGEN FOUNDER
Dr. Meredith Hay has been awarded support from the NHLBI SMARTT program for IND development of a novel peptide therapeutic to treat cognitive impairment in cardiac bypass surgery patients.